AbangeLabsGermany’s Long/Post-COVID Annex VI move shows how weak comparative evidence can still reshape reimbursable care pathways when unmet need is high. https://www.mattheneus.com/editorial/g-ba-long-post-covid-annex-vi-off-label-four-drugs-evidence-lineage-2026-04-02 #HTA #EvidenceSynthesis #HealthEconomics
Germany opens reimbursable Long/Post-COVID off-label use for four medicines
Germany's Federal Joint Committee has moved four Long/Post-COVID off-label recommendations into reimbursable care. The evidence basis is uneven across the package: metformin is anchored in the COVID-OUT randomised controlled trial, while ivabradine, vortioxetine and agomelatine rely on smaller symptom-specific studies with important transferability and bias questions.